You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model
Free

Authors

Citation

Sullivan K, Ertl L, Miao Z, et al
499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0499

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.